Navigation Links
New publication in European Urology demonstrates value of PredicineCARE liquid biopsy test for monitoring PD-L1 immunotherapy in patients with metastatic prostate cancer
Date:9/18/2021

Predicine, Inc. announced today results from a liquid biopsy study demonstrating the clinical application of utilizing the PredicineCARE liquid biopsy NGS assay to serially monitor changes in ctDNA levels in patients with metastatic castration-resistant prostate cancer (mCRPC).

The European Urology study evaluated the effects of administering a single fraction of SABR prior to the first and second doses of avelumab (PD-L1 immunotherapy drug) in patients with mCRPC. The study is entitled “Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial”. PredicineCARE, PredicineRNA and Low Pass-Whole Genome Sequencing (LP-WGS) assays were utilized in the study to monitor changes at cfDNA and cfRNA levels. The study demonstrated the potential value of serial monitoring of ctDNA levels in patients with mCRPC.

Due to the amount of time required to observe clinical or radiographic evidence of treatment efficacy, there is an unmet clinical need to utilize liquid biopsy assays to more quickly and non-invasively identify mCRPC patients who are responding to therapy. The data from this study suggests that baseline AR alterations, MYC gains, and high levels of baseline ctDNA fractions may be associated with a poorer prognosis. The study also demonstrates the potential for ctDNA analysis to identify patients who are responding to treatment prior to clinical and radiographic responses. Additionally, serial monitoring of ctDNA alternations and changes in copy number alterations demonstrate the ability to detect potential resistance mechanisms.

“This prospective study demonstrates the value of Predicine’s liquid biopsy solutions to monitor treatment response in patients receiving immunotherapy,” said Dr. Shidong Jia, Founder and CEO at Predicine. “We are pleased to provide a range of innovative liquid biopsy solutions that may have profound clinical implications including predicting patient survival, selecting therapies for treatment, monitoring for treatment response, and understanding subsequent resistance. Predicine was founded to address these types of unmet clinical needs. Our goal is to detect cancer early and treat early stages of cancer.”

The publications can be found online at: https://www.predicine.com/publications/

About Predicine
Predicine is a molecular insights company in Silicon Valley that is committed to advancing biomarker-driven precision medicine. Predicine has developed a breakthrough cell-free DNA and cell-free RNA based liquid biopsy technology for non-invasive cancer profiling, disease monitoring, assessing minimal residual disease, and early cancer detection. The company has launched a portfolio of blood-based and urine-based assays for solid tumors and hematologic malignancies. Through its CLIA and CAP facilities in the US and China, Predicine partners with leading biopharma companies and hospitals to support global clinical trials, CDx development and personalized cancer care. Further information is available on the company’s website, http://www.predicine.com. Stay in touch on LinkedIn or on Twitter @Predicine.

Read the full story at https://www.prweb.com/releases/new_publication_in_european_urology_demonstrates_value_of_predicinecare_liquid_biopsy_test_for_monitoring_pd_l1_immunotherapy_in_patients_with_metastatic_prostate_cancer/prweb18198022.htm.


'/>"/>
Source: PRWeb
Copyright©2021 Vocus, Inc.
All rights reserved


Related biology news :

1. Federal Publications Seminars Announces the Launch of FPSOnline 2.0 for Government Contracting Professionals
2. OrthoSpace Announces Publication in Arthroscopy Describing Biomechanical Performance of InSpace™ Balloon Versus Superior Capsular Reconstruction
3. Nativis Announces Publication of Study in Patients with Recurrent Glioblastoma (rGBM)
4. Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream
5. Re-publication of Flora of Northumberland and Durham (1831): A dramatic account of change
6. Neurotropes Approach to Treating Alzheimers Disease Through Its Product Bryostatin-1, an Activator of Protein Kinase C Epsilon (PKCe), Supported by Blanchette Rockefeller Neurosciences Institute (BRNI) Publication, Identifying PKCe as a Biomarker
7. RHM announces publication latest issue: Population, environment & sustainable development
8. SEPM announces the publication of a new book
9. Oxford University Press to publish Entomological Society of America publications in 2015
10. GEN Publishing introduces Clinical OMICs digital publication
11. Huma Rana, M.D., receives 2014 Richard King Award for best publication, Genetics in Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology: